Amplitude Venture Capital
VC Fund
Montréal, Canada
Amplitude Venture Capital is a VC fund in Montréal focused on Biotechnology and Health Care. Amplitude Venture Capital deploys a growth model that has successfully been used to build Canadian companies with world-class management teams and scale companies to breakout potential. Since 2012 Amplitude's founding team has raised over $700 million of equity capital in private and public markets. Amplitude, with offices in Montreal,Toronto, and Vancouver, launched its first private capital fund in November 2019, a $200-million fund that applies a proven, evidence-based approach to investing in leading Canadian precision medicine companies.
- Total investments:
- 37
- Last investment:
- Lead investor:
- 41%
- Fund size:
- $193M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Amplitude Venture Capital invests in
Stages Amplitude Venture Capital invests in
Countries Amplitude Venture Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $7M–$18M
- Series A
- $3.2M–$85M
- Series B
- $35M–$142M
Investment Focus
Industry
- Biotechnology 19 (51%)
- Health Care 15 (41%)
- Therapeutics 8 (22%)
- Medical 7 (19%)
- Life Science 7 (19%)
Stage
- Series B 9 (24%)
- Series A 8 (22%)
- Seed 6 (16%)
- Venture - Series Unknown 3 (8%)
- Post-IPO Equity 2 (5%)
Country
- Canada 20 (54%)
- United States 4 (11%)
- Israel 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Michael Mee
Principal
|
Principal | Total investments: 0 | Find email | |
Allyson Tighe
Co-Founder & Investor
|
Co-Founder & Investor | Total investments: 1 | Find email | |
Jean-François Pariseau
Co-Founder and Partner
|
Co-Founder and Partner | Total investments: 13 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Congruence Therapeutics operates as a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding. | $39.5M / Venture - Series Unknown / Mar 19, 2026 | ||
| Mediar Therapeutics is a biotechnology company that develops antibody-based medicines and biologic therapies to address cancer, autoimmune diseases, and other serious health conditions. Its research platform focuses on engineering multi-specific antibodies and modular biologics that can engage multiple biological targets or pathways simultaneously,enabling precise modulation of immune responses. The company’s pipeline includes therapeutic candidates designed to activate or inhibit specific immune functions, with the goal of improving clinical outcomes in oncology and immune-mediated disorders. Mediar Therapeutics also works on scalable manufacturing processes and collaborates with scientific partners to advance its biologics from discovery through clinical development. Its approach integrates protein engineering, immunology, and translational research to create biologic medicines that address complex disease mechanisms. The company continues to refine its technology and expand its therapeutic programs to support future clinical and regulatory progress. | $76M / Series B / Jan 07, 2026 | ||
| Thryv Therapeutics is a genetic disorder that causes a prolongation between the beginning of the QRS complex and the end of the T waveQ and T waves on the EKG, indicating a prolongation of ventricular repolarization and the action potential duration. The lengthening of this complex is associated with unexpected and life-threatening ventriculararrhythmias. Click below to learn more about our programs. | Sep 17, 2025 | ||
| Congruence Therapeutics operates as a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding. | $32M / Venture - Series Unknown / Sep 04, 2025 | ||
| Reverb Therapeutics engages in the development of treatments for cancer and other diseases. | $12M / Seed / Feb 19, 2025 | ||
| Fluid Biotech is a Calgary based company that aims to develop the next generation of stents to improve patient well-being and realise better health and quality of life through innovation. | $27M / Series A / Dec 16, 2024 | ||
| Nomic is a bioengineering company working to make the human proteome as broadly and easily accessible as the human genome. They are building the nELISA, a next-generation protein profiling platform for measuring proteins at scale and at high throughput. They offer scientists protein profiling solutions and empower them to decide the scope and scaleof their experiments. | $42M / Series B / Sep 17, 2024 | ||
| Radiant Biotherapeutics is a revolutionary antibody platform company leading the new frontier of multi-valent, multi-specific therapeutics to deliver transformative therapies for patients. | $35M / Series A / Sep 11, 2024 | ||
| Ability biologics develops novel, tailored immune modifying biotherapeutics to address unmet medical requirements in cancer and autoimmune disease patients. | $18M / Seed / Jun 18, 2024 | ||
| Ability biologics develops novel, tailored immune modifying biotherapeutics to address unmet medical requirements in cancer and autoimmune disease patients. | $12M / Seed / Dec 06, 2023 | ||
| See all 37 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Amplitude Venture Capital invest in?
Amplitude Venture Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 37 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Amplitude Venture Capital invest in?
Amplitude Venture Capital typically joins rounds of $7M–$18M at Seed, $3.2M–$85M at Series A and $35M–$142M at Series B. These are whole funding-round sizes, not Amplitude Venture Capital's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Amplitude Venture Capital took part in.
How do I contact Amplitude Venture Capital?
Public channels for Amplitude Venture Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Amplitude Venture Capital?
The team at Amplitude Venture Capital includes Michael Mee (Principal), Allyson Tighe (Co-Founder & Investor) and Jean-François Pariseau (Co-Founder and Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
